Autologous chondrocyte implantation - Histogenics

Drug Profile

Autologous chondrocyte implantation - Histogenics

Alternative Names: NeoCart

Latest Information Update: 21 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Histogenics Corporation
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Cartilage disorders

Most Recent Events

  • 15 Mar 2018 Autologous chondrocyte implantation - Histogenics is available for licensing in countries (excluding North America) as of 15 March 2018.
  • 15 Mar 2018 Histogenics expects to launch NeoCart® in USA in the fourth quarter of 2019
  • 15 Mar 2018 Histogenics and MEDINET plan a phase III trial for Cartilage disorders in Japan in the second half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top